Nothing is going right for Amgen these days. It now says its experimental osteoporosis treatment, Evenity, is unlikely to win approval from the Food and Drug Administration this year.
from WSJ.com: Markets http://ift.tt/2qa58Ug
via https://ifttt.com/ IFTTT
No comments:
Post a Comment